Researcher
Franki Speleman
- Disciplines:Cell signalling, Cellular interactions and extracellular matrix, Cytoskeleton, Epigenetics, Cell death, Cell division, Cell growth and development, Cell movement, Transcription and translation, Medical epigenomics, Medical metagenomics, Medical genomics, Genetics, Molecular and cell biology not elsewhere classified, Intracellular compartments and transport, Membrane structure and transport, Posttranslational modifications, Stem cell biology, Structural biology, Immunogenetics, Clinical genetics and molecular diagnostics
Affiliations
- Department of Biomolecular Medicine (Department)
Member
From1 Oct 2018 → Today - Department of Pediatrics and medical genetics (Department)
Member
From1 Jan 1993 → 30 Sep 2018
Projects
1 - 10 of 44
- Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate studentsFrom1 May 2024 → TodayFunding: BOF - doctoral mandates
- Spatial-omics deciphering of cellular and molecular responses to enhanced MYCN/ATR-CHK1 synthetic lethality in high-risk neuroblastomaFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Incucyte S3: Comprehensive cellular phenotyping using high-throughput live cell imagingFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapiesFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- SpatialConnect: linking tissue biology to the new era of single-cell spatial transcriptomicsFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Replication fork protector dependency factors: novel targets for combination treatment and immunomodulation in neuroblastoma (REINFORCE)From1 Jan 2022 → TodayFunding: BOF - projects
- Scrutinizing selective Aurora Kinase A inhibition as a novel entry point for synthetic lethality in neuroblastomaFrom1 Nov 2021 → TodayFunding: FWO fellowships
- The role of the SOX11 lineage-dependency factor as epigenetic master regulator in neuroblastomaFrom1 Oct 2021 → TodayFunding: BOF - projects
- The role of BRIP1 in MYCN driven neuroblastoma formation: from mechanism to druggingFrom1 Jan 2021 → TodayFunding: FWO Humanitarian research project Stand up against Cancer
- Targeting the degradation of proteins involved in neuroblastoma with bivalent ligands.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 91
- MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression(2024)
Authors: Alice Salib, Nisitha Jayatilleke, Janith A. Seneviratne, Chelsea Mayoh, Katleen De Preter, Franki Speleman, Belamy B. Cheung, Daniel R. Carter, Glenn M. Marshall
Pages: 363 - 377 - HTSplotter : an end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening(2024)
Authors: Carolina de Carvalho Nunes, Jasper Anckaert, Fanny De Vloed, Jolien De Wyn, Kaat Durinck, Jo Vandesompele, Franki Speleman, Vanessa Vermeirssen
- Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma(2024)
Authors: Stéphane Van Haver, Yujie Fan, Sarah-Lee Bekaert, Celine Everaert, Wouter Van Loocke, Vittorio Zanzani, Joke Deschildre, Ines Fernandez Maestre, Adrianna Amaro, Vanessa Vermeirssen, et al.
- Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN(2024)
Authors: Jonatan Linus Gabre, Peter Merseburger, Arne Claeys, Joachim Siaw, Sarah-Lee Bekaert, Franki Speleman, Bengt Hallberg, Ruth H Palmer, Jimmy Van den Eynden
- Exploration of neuroblastoma xenograft models for tumor extracellular RNA profiling in murine blood plasma(2023)
Authors: Jill Deleu, Hanne Van Droogenbroeck, Jasper Anckaert, Anneleen Decock, Jilke De Wilde, Kaat Durinck, Liselot Mus, Justine Nuytens, Muhammad Rishfi, Kathleen Schoofs, et al.
- Mitotic dysregulation at tumor initiation creates a therapeutic vulnerability to combination anti-mitotic and pro-apoptotic agents for MYCN-driven neuroblastoma(2023)
Authors: Lei Zhai, Anushree Balachandran, Rebecca Larkin, Janith A. Seneviratne, Sylvia A. Chung, Amit Lalwani, Shoma Tsubota, Dominik Beck, Kenji Kadomatsu, Anneleen Beckers, et al.
- Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma(2023)
Authors: Jordan F. Hastings, Sharissa L. Latham, Alvin Kamili, Madeleine S. Wheatley, Jeremy Z. R. Han, Marie Wong-Erasmus, Monica Phimmachanh, Max Nobis, Chiara Pantarelli, Antonia L. Cadell, et al.
- Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation(2023)
Authors: Alan Van Goethem, Jill Deleu, Nurten Yigit, Celine Everaert, Myrthala Moreno-Smith, Sanjeev A Vasudevan, Fjoralba Zeka, Eveline Barbieri, Franki Speleman, Pieter Mestdagh, et al.
- Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA(2022)
Authors: Vanessa Vermeirssen, Jill Deleu, Annelien Morlion, Celine Everaert, Jilke De Wilde, Jasper Anckaert, Kaat Durinck, Justine Nuytens, Muhammad Rishfi, Franki Speleman, et al.
- RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition(2022)
Authors: Carolina de Carvalho Nunes, Lisa Depestel, Liselot Mus, Kaylee M. Keller, Louis Delhaye, Amber Louwagie, Muhammad Rishfi, Alex Whale, Neesha Kara, Simon R. Andrews, et al.
Patents
1 - 1 of 1